VeraTag™ Technology The VeraTag technology is a proximity-based method designed to detect and quantify protein-protein complexes, including dimers, of the HER family of receptor tyrosine kinases, in FFPE specimens.

Multi-labeled antibodies are directed to different epitopes on the same or associated protein partner.	Activation of "molecular scissor" liberates singlet oxygen, cleaving all tethers within a designated range.	Released VeraTag reporters are quantified by capillary electrophoresis.

The HER1 and HER3 Quantitative Protein Assays now available for clinical development use. The HER1 and HER3 protein assays provide unique, quantitative measurements of protein expression and activity in formalin fixed paraffin embedded (FFPE) tumor samples. These assays supplement HERmark™, Monogram's HER2 Total and HER2 Homodimer Breast Cancer Assay, and expands the potential clinical reach of VeraTag assays to lung, colorectal and other cancers. Click here for information on clinical studies.

For more information on our research use assays email us at biomarker-studies@monogrambio.com.